Prothrombin complex concentrates in emergency bleeding disorders

American Journal of Hematology

Volumn 87, Issue 9, 2012, Pages 898-902

  Rodgers, George M ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; FATTY ACID BINDING PROTEIN; FRESH FROZEN PLASMA; HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN COMPLEX; PROTHROMBINEX; RECOMBINANT BLOOD CLOTTING FACTOR 9; UMAN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANAPHYLAXIS; ANTICOAGULATION; BLEEDING; BLEEDING DISORDER; CARDIOVASCULAR RISK; CHILL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEVER; HEART INFARCTION; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; HYPERSENSITIVITY REACTION; HYPERTENSION; INJURY; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; URTICARIA; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; EMERGENCY MEDICAL SERVICES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO;

EID: 84865396554     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23254     Document Type: Review

References (56)

1. Samama CM. Prothrombin complex concentrates: A brief review. Eur J Anaesthesiol 2008; 25: 784-789.
2. Key NS, Negrier C. Coagulation factor concentrates: Past, present, and future. Lancet 2007; 370: 439-448.
3. Guyatt GH, Akl EA, Crowther M, et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive Summary. ACCP Evidence-Based Clinical Practice Guidelines (9th Edition). Chest 2012; 141( Suppl): 7S-14S.
4. Sørensen B, Spahn DR, Innerhofer P, et al. Clinical review: Prothrombin complex concentrates-Evaluation of safety and thrombogenicity. Crit Care 2011; 15: 201.
5. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008; 62: 1614-1622.
6. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: Management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 2010; 29: 171-181.
7. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: A prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-631.
8. Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: A review of the literature. Neurocrit Care 2010; 12: 403-413.
9. Baxter Health Care Corp. Feiba NF (anti-inhibitor coagulant complex) [package insert]. Deerfield, IL: Baxter Health Care Corp.; 2011.
10. Makris M, Van Veen JJ. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? Blood Transfus 2011; 9: 117-119.
11. Baxter Healthcare Corp. Bebulin VH [package insert]. Westlake Village, CA: Baxter Healthcare Corp.; 2001.
12. CSL Behring Canada. Beriplex P/N (human prothrombin complex) [product monograph]. Ottawa, ON: CSL Behring Canada; 2010.
13. Sanquin. Cofact [package insert]. Amsterdam, The Netherlands: Sanquin; 2006.
14. Kaskadil [prescribing information]. Available at: http://www.doctissimo.fr/medicament-KASKADIL.htm. Accessed on January 4, 2012.
15. Octapharma. Octaplex [prescribing information]. Vienna, Austria: Octapharma; 2008.
16. Grifols. Profilnine SD [package insert]. Los Angeles, CA: Grifols; 2004.
17. Baxter Healthcare Corp. Proplex T [package insert]. Westlake Village, CA: Baxter Healthcare Corp.; 2002.
18. CSL Limited. Prothrombinex-VF [package insert]. Victoria, Australia: CSL Limited; 2011.
19. Kedrion S.p.A. Uman Complex [package insert]. Barga, Italy: Kedrion S.p.A.; 2002.
20. Morgenstern LB, Hemphill JC III, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41: 2108-2129.
21. National Advisory Committee on Blood and Blood Products. Recommendations for use of Octaplex® in Canada. Available at: http://www.gov.ns.ca/health/nspbcp/docs/NAC%20octaplex%20recommendations.pdf. September 16, 2008. Accessed on October 27, 2011.
22. Canadian Blood Services. Availability of Beriplex® P/N (Human prothrombin complex). Available at: http://www.blood.ca/CentreApps/Internet/UW_V502_ MainEngine.nsf/resources/CustomerLetters2011/$file/CL2011-20.pdf. August 2, 2011. Accessed on December 8, 2011.
23. Grobler C, Callum J, McCluskey SA. Reversal of vitamin K antagonists prior to urgent surgery. Can J Anaesth 2010; 57: 458-467.
24. Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications-Clinical presentation and therapeutic options. Thromb Res 2008; 122: S13-S18.
25. Pabinger I, Tiede A, Kalina U, et al. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: A prospective clinical trial of emergency anticoagulation reversal. Ann Hematol 2010; 89: 309-316.
26. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
27. Lorenz R, Kienast J, Otto U, et al. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: A prospective clinical study. Blood Coagul Fibrinolysis 2007; 18: 565-570.
28. Preston FE, Laidlaw ST, Sampson B, et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): Efficacy and safety in 42 patients. Br J Haematol 2002; 116: 619-624.
29. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res 2006; 118: 313-320.
30. Vigue B, Ract C, Tremey B, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33: 721-725.
31. Riess HB, Meier-Hellmann A, Motsch J, et al. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121: 9-16.
32. Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-970.
33. Crawford JH, Augustson BM. Prothrombinex use for the reversal of warfarin: Is fresh frozen plasma needed? Med J Aust 2006; 184: 365-366.
34. Tran H, Collecutt M, Whitehead S, Salem HH. Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation. Intern Med J 2011; 41: 337-343.
35. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-977.
36. Imberti D, Barillari G, Biasioli C, et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus 2011; 9: 148-155.
37. Kuwashiro T, Yasaka M, Itabashi R, et al. Effect of prothrombin complex concentrate on hematoma enlargement and clinical outcome in patients with anticoagulant-associated intracerebral hemorrhage. Cerebrovasc Dis 2011; 31: 170-176.
38. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol 2008; 83: 137-143.
39. Patanwala AE, Acquisto NM, Erstad BL. Prothrombin complex concentrate for critical bleeding. Ann Pharmacother 2011; 45: 990-999.
40. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-480.
41. Demeyere R, Gillardin S, Arnout J, et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: A randomized study. Vox Sang 2010; 99: 251-260.
42. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37: 1465-1470.
43. Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. Clin Ther 2010; 32: 2478-2493.
44. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa® (dabigatran etexilate mesylate) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2011.
45. Janssen Pharmaceuticals, Inc. Xarelto® (rivaroxaban) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011.
46. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115: 15-20.
47. Levi MM, Eerenberg E, Löwenberg E, et al. Bleeding in patients using new anticoagulants or antiplatelet agents: Risk factors and management. Neth J Med 2010; 68: 68-76.
48. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
49. Schick KS, Fertmann JM, Jauch KW, et al. Prothrombin complex concentrate in surgical patients: Retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care 2009; 13: R191.
50. Meyer MA, Ostrowski SR, Windelov NA, et al. Fibrinogen concentrates for bleeding trauma patients: What is the evidence? Vox Sang 2011; 101: 185-190.
51. Chapman SA, Irwin ED, Beal AL, et al. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother 2011; 45: 869-875.
52. Lorenz R, Kienast J, Otto U, et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003; 15: 15-20.
53. Fuentes-Garcia D, Hernandez-Palazon J, Sansano-Sanchez T, et al. Prothrombin complex concentrate in the treatment of multitransfusion dilutional coagulopathy in a paediatric patient. Br J Anaesth 2011; 106: 912-913.
54. Holness L, Knippen MA, Simmons L, et al. Fatalities caused by TRALI. Transfus Med Rev 2004; 18: 184-188.
55. Franchini M, Lippi G. Prothrombin complex concentrates: An update. Blood Transfus 2010; 8: 149-154.
56. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106: 429-438.